Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 50 of 117

    1.

    Preclinical evaluation of the novel small-molecule integrin alpha5beta1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization.

    Zahn G, Vossmeyer D, Stragies R, Wills M, Wong CG, Löffler KU, Adamis AP, Knolle J.

    Arch Ophthalmol. 2009 Oct;127(10):1329-35.PMID: 19822850 [PubMed - indexed for MEDLINE]Related articles

    2.

    Assessment of the Integrin {alpha}5{beta}1 Antagonist JSM6427 in Proliferative Vitreoretinopathy Using in Vitro Assays and a Rabbit Model of Retinal Detachment.

    Zahn G, Volk K, Lewis GP, Vossmeyer D, Stragies R, Heier JS, Daniel PE, Adamis AP, Chapin EA, Fisher SK, Holz FG, Loeffler KU, Knolle J.

    Invest Ophthalmol Vis Sci. 2009 Oct 8. [Epub ahead of print]PMID: 19815730 [PubMed - as supplied by publisher]Related articles

    3.

    The rationale for drug combinations in age-related macular degeneration.

    Adamis AP.

    Retina. 2009 Jun;29(6 Suppl):S42-4.PMID: 19553800 [PubMed - indexed for MEDLINE]Related articles

    4.

    Judah Folkman.

    Adamis AP, Miller JW.

    Semin Ophthalmol. 2009 May-Jun;24(3):128-9. No abstract available. PMID: 19437346 [PubMed - indexed for MEDLINE]Related articles

    5.

    Pegaptanib sodium for macular edema secondary to central retinal vein occlusion.

    Wroblewski JJ, Wells JA 3rd, Adamis AP, Buggage RR, Cunningham ET Jr, Goldbaum M, Guyer DR, Katz B, Altaweel MM; Pegaptanib in Central Retinal Vein Occlusion Study Group.

    Arch Ophthalmol. 2009 Apr;127(4):374-80.PMID: 19365011 [PubMed - indexed for MEDLINE]Related articles

    6.

    Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial.

    Singerman LJ, Masonson H, Patel M, Adamis AP, Buggage R, Cunningham E, Goldbaum M, Katz B, Guyer D.

    Br J Ophthalmol. 2008 Dec;92(12):1606-11. Epub 2008 Jul 9.PMID: 18614570 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Immunological mechanisms in the pathogenesis of diabetic retinopathy.

    Adamis AP, Berman AJ.

    Semin Immunopathol. 2008 Apr;30(2):65-84. Epub 2008 Mar 14. Review.PMID: 18340447 [PubMed - indexed for MEDLINE]Related articles

    8.

    Simultaneous but not prior inhibition of VEGF165 enhances the efficacy of photodynamic therapy in multiple models of ocular neovascularization.

    Ju M, Mailhos C, Bradley J, Dowie T, Ganley M, Cook G, Calias P, Lange N, Adamis AP, Shima DT, Robinson GS.

    Invest Ophthalmol Vis Sci. 2008 Feb;49(2):662-70.PMID: 18235012 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity.

    Javitt JC, Zlateva GP, Earnshaw SR, Pleil AM, Graham CN, Brogan AJ, Shah SN, Adamis AP.

    Value Health. 2008 Jul-Aug;11(4):563-74. Epub 2007 Dec 17.PMID: 18179676 [PubMed - indexed for MEDLINE]Related articles

    10.

    Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.

    Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, Akita J, Samuelsson SJ, Robinson GS, Adamis AP, Shima DT.

    Am J Pathol. 2007 Jul;171(1):53-67.PMID: 17591953 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration.

    Macugen AMD Study Group, Apte RS, Modi M, Masonson H, Patel M, Whitfield L, Adamis AP.

    Ophthalmology. 2007 Sep;114(9):1702-12. Epub 2007 May 23.PMID: 17509689 [PubMed - indexed for MEDLINE]Related articles

    12.

    Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice.

    Zhong L, Bradley J, Schubert W, Ahmed E, Adamis AP, Shima DT, Robinson GS, Ng YS.

    Invest Ophthalmol Vis Sci. 2007 Mar;48(3):1212-8.PMID: 17325165 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products.

    Kaji Y, Usui T, Ishida S, Yamashiro K, Moore TC, Moore J, Yamamoto Y, Yamamoto H, Adamis AP.

    Invest Ophthalmol Vis Sci. 2007 Feb;48(2):858-65.PMID: 17251488 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy.

    Starita C, Patel M, Katz B, Adamis AP.

    Dev Ophthalmol. 2007;39:122-48. Review.PMID: 17245083 [PubMed - indexed for MEDLINE]Related articles

    15.

    Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases.

    Ng EW, Adamis AP.

    Ann N Y Acad Sci. 2006 Oct;1082:151-71. Review.PMID: 17145936 [PubMed - indexed for MEDLINE]Related articles

    16.

    Inhibitory effect of an antibody to cryptic collagen type IV epitopes on choroidal neovascularization.

    Jo N, Ju M, Nishijima K, Robinson GS, Adamis AP, Shima DT, Mailhos C.

    Mol Vis. 2006 Oct 26;12:1243-9.PMID: 17110907 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Molecular biology of choroidal neovascularization.

    Lu M, Adamis AP.

    Ophthalmol Clin North Am. 2006 Sep;19(3):323-34. Review.PMID: 16935207 [PubMed - indexed for MEDLINE]Related articles

    18.

    Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.

    VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, Chakravarthy U, Adamis AP, Cunningham ET Jr, Goldbaum M, Guyer DR, Katz B, Patel M.

    Ophthalmology. 2006 Sep;113(9):1508.e1-25. Epub 2006 Jul 7.PMID: 16828500 [PubMed - indexed for MEDLINE]Related articles

    19.

    Proceedings of the Third International Symposium on Retinopathy of Prematurity: an update on ROP from the lab to the nursery (November 2003, Anaheim, California).

    Lutty GA, Chan-Ling T, Phelps DL, Adamis AP, Berns KI, Chan CK, Cole CH, D'Amore PA, Das A, Deng WT, Dobson V, Flynn JT, Friedlander M, Fulton A, Good WV, Grant MB, Hansen R, Hauswirth WW, Hardy RJ, Hinton DR, Hughes S, McLeod DS, Palmer EA, Patz A, Penn JS, Raisler BJ, Repka MX, Saint-Geniez M, Shaw LC, Shima DT, Smith BT, Smith LE, Tahija SG, Tasman W, Trese MT.

    Mol Vis. 2006 May 23;12:532-80.PMID: 16735995 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization.

    Jo N, Mailhos C, Ju M, Cheung E, Bradley J, Nishijima K, Robinson GS, Adamis AP, Shima DT.

    Am J Pathol. 2006 Jun;168(6):2036-53.PMID: 16723717 [PubMed - indexed for MEDLINE]Related articlesFree article

    21.

    Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.

    VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, D'Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET Jr, Guyer DR, Katz B.

    Ophthalmology. 2006 Jun;113(6):992-1001.e6. Epub 2006 Apr 27.PMID: 16647134 [PubMed - indexed for MEDLINE]Related articles

    22.

    Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.

    Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP.

    Nat Rev Drug Discov. 2006 Feb;5(2):123-32. Review.PMID: 16518379 [PubMed - indexed for MEDLINE]Related articles

    23.

    Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals.

    Adamis AP, Altaweel M, Bressler NM, Cunningham ET Jr, Davis MD, Goldbaum M, Gonzales C, Guyer DR, Barrett K, Patel M; Macugen Diabetic Retinopathy Study Group.

    Ophthalmology. 2006 Jan;113(1):23-8. Epub 2005 Dec 15.PMID: 16343627 [PubMed - indexed for MEDLINE]Related articles

    24.

    A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema.

    Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ, Goldbaum M, Guyer DR, Katz B, Patel M, Schwartz SD; Macugen Diabetic Retinopathy Study Group.

    Ophthalmology. 2005 Oct;112(10):1747-57.PMID: 16154196 [PubMed - indexed for MEDLINE]Related articles

    25.

    Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration.

    Ng EW, Adamis AP.

    Can J Ophthalmol. 2005 Jun;40(3):352-68. Review.PMID: 15947805 [PubMed - indexed for MEDLINE]Related articlesFree article

    26.

    The role of vascular endothelial growth factor in ocular health and disease.

    Adamis AP, Shima DT.

    Retina. 2005 Feb-Mar;25(2):111-8. Review.PMID: 15689799 [PubMed - indexed for MEDLINE]Related articles

    27.

    Pegaptanib for neovascular age-related macular degeneration.

    Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group.

    N Engl J Med. 2004 Dec 30;351(27):2805-16.PMID: 15625332 [PubMed - indexed for MEDLINE]Related articlesFree article

    28.

    Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy.

    Poulaki V, Joussen AM, Mitsiades N, Mitsiades CS, Iliaki EF, Adamis AP.

    Am J Pathol. 2004 Aug;165(2):457-69.PMID: 15277220 [PubMed - indexed for MEDLINE]Related articlesFree article

    29.

    A central role for inflammation in the pathogenesis of diabetic retinopathy.

    Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, Schraermeyer U, Kociok N, Fauser S, Kirchhof B, Kern TS, Adamis AP.

    FASEB J. 2004 Sep;18(12):1450-2. Epub 2004 Jul 1.PMID: 15231732 [PubMed - indexed for MEDLINE]Related articlesFree article

    30.

    Ocular delivery of angiostatic agents.

    Lu M, Adamis AP.

    Int Ophthalmol Clin. 2004 Summer;44(3):41-51. Review. No abstract available. PMID: 15211176 [PubMed - indexed for MEDLINE]Related articles

    31.

    VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2.

    Usui T, Ishida S, Yamashiro K, Kaji Y, Poulaki V, Moore J, Moore T, Amano S, Horikawa Y, Dartt D, Golding M, Shima DT, Adamis AP.

    Invest Ophthalmol Vis Sci. 2004 Feb;45(2):368-74.PMID: 14744874 [PubMed - indexed for MEDLINE]Related articlesFree article

    32.

    Angiogenesis and ophthalmic disease.

    Adamis AP, Aiello LP, D'Amato RA.

    Angiogenesis. 1999;3(1):9-14.PMID: 14517440 [PubMed]Related articles

    33.

    The role of advanced glycation end products in retinal microvascular leukostasis.

    Moore TC, Moore JE, Kaji Y, Frizzell N, Usui T, Poulaki V, Campbell IL, Stitt AW, Gardiner TA, Archer DB, Adamis AP.

    Invest Ophthalmol Vis Sci. 2003 Oct;44(10):4457-64.PMID: 14507893 [PubMed - indexed for MEDLINE]Related articlesFree article

    34.

    VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization.

    Ishida S, Usui T, Yamashiro K, Kaji Y, Amano S, Ogura Y, Hida T, Oguchi Y, Ambati J, Miller JW, Gragoudas ES, Ng YS, D'Amore PA, Shima DT, Adamis AP.

    J Exp Med. 2003 Aug 4;198(3):483-9.PMID: 12900522 [PubMed - indexed for MEDLINE]Related articlesFree article

    35.

    Inhibition of corneal neovascularization by genetic ablation of CCR2.

    Ambati BK, Joussen AM, Kuziel WA, Adamis AP, Ambati J.

    Cornea. 2003 Jul;22(5):465-7.PMID: 12827053 [PubMed - indexed for MEDLINE]Related articles

    36.

    Platelets accumulate in the diabetic retinal vasculature following endothelial death and suppress blood-retinal barrier breakdown.

    Yamashiro K, Tsujikawa A, Ishida S, Usui T, Kaji Y, Honda Y, Ogura Y, Adamis AP.

    Am J Pathol. 2003 Jul;163(1):253-9.PMID: 12819029 [PubMed - indexed for MEDLINE]Related articlesFree article

    37.

    Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization.

    Sakurai E, Taguchi H, Anand A, Ambati BK, Gragoudas ES, Miller JW, Adamis AP, Ambati J.

    Invest Ophthalmol Vis Sci. 2003 Jun;44(6):2743-9.PMID: 12766082 [PubMed - indexed for MEDLINE]Related articlesFree article

    38.

    Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies.

    Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP.

    Surv Ophthalmol. 2003 May-Jun;48(3):257-93. Review.PMID: 12745003 [PubMed - indexed for MEDLINE]Related articles

    39.

    Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease.

    Ishida S, Yamashiro K, Usui T, Kaji Y, Ogura Y, Hida T, Honda Y, Oguchi Y, Adamis AP.

    Nat Med. 2003 Jun;9(6):781-8. Epub 2003 May 5.PMID: 12730690 [PubMed - indexed for MEDLINE]Related articles

    40.

    VEGF164 is proinflammatory in the diabetic retina.

    Ishida S, Usui T, Yamashiro K, Kaji Y, Ahmed E, Carrasquillo KG, Amano S, Hida T, Oguchi Y, Adamis AP.

    Invest Ophthalmol Vis Sci. 2003 May;44(5):2155-62.PMID: 12714656 [PubMed - indexed for MEDLINE]Related articlesFree article

    41.

    Endothelial-directed hepatic regeneration after partial hepatectomy.

    Greene AK, Wiener S, Puder M, Yoshida A, Shi B, Perez-Atayde AR, Efstathiou JA, Holmgren L, Adamis AP, Rupnick M, Folkman J, O'Reilly MS.

    Ann Surg. 2003 Apr;237(4):530-5.PMID: 12677150 [PubMed - indexed for MEDLINE]Related articlesFree article

    42.

    Characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes: role of oxidants and protein kinase-C activation.

    Abiko T, Abiko A, Clermont AC, Shoelson B, Horio N, Takahashi J, Adamis AP, King GL, Bursell SE.

    Diabetes. 2003 Mar;52(3):829-37.PMID: 12606527 [PubMed - indexed for MEDLINE]Related articlesFree article

    43.

    Sustained inhibition of corneal neovascularization by genetic ablation of CCR5.

    Ambati BK, Anand A, Joussen AM, Kuziel WA, Adamis AP, Ambati J.

    Invest Ophthalmol Vis Sci. 2003 Feb;44(2):590-3.PMID: 12556387 [PubMed - indexed for MEDLINE]Related articlesFree article

    44.

    Expression and function of receptors for advanced glycation end products in bovine corneal endothelial cells.

    Kaji Y, Amano S, Usui T, Oshika T, Yamashiro K, Ishida S, Suzuki K, Tanaka S, Adamis AP, Nagai R, Horiuchi S.

    Invest Ophthalmol Vis Sci. 2003 Feb;44(2):521-8.PMID: 12556378 [PubMed - indexed for MEDLINE]Related articlesFree article

    45.

    Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres.

    Carrasquillo KG, Ricker JA, Rigas IK, Miller JW, Gragoudas ES, Adamis AP.

    Invest Ophthalmol Vis Sci. 2003 Jan;44(1):290-9.PMID: 12506087 [PubMed - indexed for MEDLINE]Related articlesFree article

    46.

    VEGF-dependent conjunctivalization of the corneal surface.

    Joussen AM, Poulaki V, Mitsiades N, Stechschulte SU, Kirchhof B, Dartt DA, Fong GH, Rudge J, Wiegand SJ, Yancopoulos GD, Adamis AP.

    Invest Ophthalmol Vis Sci. 2003 Jan;44(1):117-23.PMID: 12506063 [PubMed - indexed for MEDLINE]Related articlesFree article

    47.

    Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes.

    Joussen AM, Poulaki V, Mitsiades N, Cai WY, Suzuma I, Pak J, Ju ST, Rook SL, Esser P, Mitsiades CS, Kirchhof B, Adamis AP, Aiello LP.

    FASEB J. 2003 Jan;17(1):76-8. Epub 2002 Nov 15.PMID: 12475915 [PubMed - indexed for MEDLINE]Related articlesFree article

    48.

    The inflammatory milieu associated with conjunctivalized cornea and its alteration with IL-1 RA gene therapy.

    Moore JE, McMullen TC, Campbell IL, Rohan R, Kaji Y, Afshari NA, Usui T, Archer DB, Adamis AP.

    Invest Ophthalmol Vis Sci. 2002 Sep;43(9):2905-15.PMID: 12202509 [PubMed - indexed for MEDLINE]Related articlesFree article

    49.

    The corneal epithelial stem cell.

    Moore JE, McMullen CB, Mahon G, Adamis AP.

    DNA Cell Biol. 2002 May-Jun;21(5-6):443-51.PMID: 12167247 [PubMed - indexed for MEDLINE]Related articles

    50.

    Angiostatin inhibits and regresses corneal neovascularization.

    Ambati BK, Joussen AM, Ambati J, Moromizato Y, Guha C, Javaherian K, Gillies S, O'Reilly MS, Adamis AP.

    Arch Ophthalmol. 2002 Aug;120(8):1063-8.PMID: 12149060 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Find related data

    Search details

    » See more...